You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
東瑞製藥(02348.HK)擬不超2.4億元受讓非布司他片及原料藥的上市許可
格隆匯 12-24 23:00

格隆匯12月24日丨東瑞製藥(02348.HK)公佈,於2019年12月24日,蘇州東瑞(公司的間接全資附屬公司)與南京海納訂立上市許可持有人轉讓協議,據此南京海納將有關非布司他片(40mg,80mg)及原料藥的上市許可持有人轉讓予蘇州東瑞,總代價最多為人民幣2.4億元。

南京海納為根據中國法律註冊成立的公司,其主要從事研發醫藥產品及銷售化學產品業務。有關非布司他片(40mg,80mg)及原料藥的上市許可持有人的轉讓,就非布司他片(40mg,80mg)的生產許可已作出申請,且預期將於2020年10月31日前取得許可。南京海納亦會將相關技術知識及權利轉讓予蘇州東瑞。

公司稱,非布司他為一款臨牀指南推薦用於治療因尿酸水平高而引致痛風的藥物,且收錄在中國國家醫療保險涵蓋的國家藥物目錄中。董事留意到,中國的高尿酸血癥患者數量不斷增加,治療痛風藥物的需求預期將有所增長。中國另有其他三間藥物生產商已獲得非布司他片的仿製藥生產批准,但尚未通過一致性評價。預期上市許可持有人轉讓協議項下擬進行的交易將擴大該集團提供的產品範圍,且該集團能憑藉其銷售網絡及資源推廣非布司他片,從而增強該集團的整體競爭力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account